Observational studyPloS one2025
1H-MRS study of hippocampus in advanced prostate cancer patients: Relationship between hippocampal secondary damage and cognitive disorder following combined androgen blockade therapy.
Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mapping Cognitive Oncology: A Decade of Trends and Research Fronts.Medical sciences (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine whether 6 months of combined androgen blockade (CAB) treatment would result in metabolic changes of hippocampus and whether metabolic changes correlate with changes in cognition in patients with advanced prostate cancer (PCa). MATERIALS AND
methodsThis is an observational study. Proton magnetic resonance spectroscopy (1H-MRS) was used to observe the changes in the ratios of N-acetylaspartate/creatine (NAA/Cr) and choline-containing compounds/creatine (Cho/Cr) on the bilateral hippocampus for the patients before and 6 months after CAB treatment. Cognitive function was also assessed by the Beijing version of the Montreal Cognitive Assessment (MoCA-BJ) at the above two time points. Additionally, a certain number of matched individuals undergoing physical examination were selected as the control group.
resultsCAB group comprised 25 patients with advanced PCa completing follow-up, while control group had 22 healthy controls. Prior to CAB, no significant differences existed in MoCA-BJ scores (including sub-scores) or bilateral hippocampal NAA/Cr and Cho/Cr ratios between groups. Six months after CAB, CAB group exhibited marked declines in MoCA-BJ total score, delayed recall, visuospatial/executive, and attention functions, alongside reduced bilateral hippocampal NAA/Cr and elevated left hippocampal Cho/Cr (P < 0.05).The results of multiple linear regression indicate a positive correlation between NAA/Cr in the left hippocampus and MoCA-BJ total score (β = 4.66, P < 0.001), as well as delayed recall function (β = 2.76, P < 0.001). Mediation analysis confirms that testosterone influences the MoCA-BJ total score and delayed recall function by affecting NAA/Cr in the left hippocampus.
conclusionsThe impact of advanced PCa on cognitive performance could be negligible. However, patients experienced secondary hippocampal injury after CAB, which further led to cognitive dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.